

Ayuda Postdoctoral AECC 2023

Adjudicatarios

Dr. Juan Enrique Ramis

Instituto de Investigación Biomédica
(IRB Barcelona)

Identification of clonal hematopoiesis
drivers and their role in cancer

Dra. Paula Aguilera

Centro Andaluz de Biología Molecular
y Medicina regenerativa (CABIMER-
CSIC)

Implications of ATRX mutations in genome
instability and therapeutic opportunities for
glioblastoma

Dr. Carlos Ruiz

Cancer Center Clínica Universidad de
Navarra (CIMA-CCUN)

A machine learning approach to improve
patients' stratification in Myelodysplastic
syndromes

Dra. Oihane Mitxelena

Instituto de Investigación Sanitaria
Biodonostia (IIS Biodonostia)

Breast cancer dormancy and bone
metastasis: bioinspired 3D models for the
study of cell-extracellular matrix interaction
as a strategy to find new therapies

Dra. Flor Navarro

Instituto de Investigación Sanitaria
Aragón (IIS Aragón)

Overcoming immune evasion in PDAC
through modulation of PPAR-delta

Dra. María Sancho

Instituto de Nanociencia y Materiales
de Aragón, INMA (CSIC-UNIZAR)

Development of exosome-based artificial
bio-nanoparticles: a novel targeted vector
with high potential in cancer therapy
(DEXTER)

Dr. Ivan Zadra

Universidad Pompeu Fabra (UPF)

Targeting p53-dependent DNA repair
pathway to boost immunotherapy response

Dra. Sandra Blasco

Instituto Hospital del Mar de
Investigaciones Médicas (IMIM)

Sensitizing ER+ Breast Cancer to immune-
checkpoint blockade therapy

Suplementes

Dr. Ivó Hernandez

Centro Nacional Investigaciones
Oncológicas (CNIO)

The role of TFEB in the development and progression of cancer as a master regulator of autophagy

Dra. Natalia Sanz

Instituto de Investigaciones Biomédicas
"Albert Sols" (CSIC-UAM)

Identification of the genetic determinants to overcome chromosomal instability in Head and Neck Squamous Cancer (HNSCC)

Dra. María Castejón

Universidad de Murcia

MGRN1 regulation of genome stability as a vulnerability for the development of novel synthetic lethal therapeutic strategies for melanoma

Dra. Ana Domostegui

Instituto de Investigación Biomédica (IRB
Barcelona)

Innovating drug discovery strategies to probe and exploit cancer vulnerabilities through protein degradation

Dr. Abel Jesús Martel

Instituto de Investigación Biomédica de
Bellvitge (IDIBELL)

Genetic and non-genetic risk, DNA repair deficiencies and tumor immune features to maximize the implementation of precision medicine in early-onset colorectal

Dra. Ana Díaz

Universidad de Oviedo

Towards early detection and precision medicine: barcoded aptasensors for unravelling the glycosylation signature of pancreatic cancer

Dra. Silvana Maas

Vall d'Hebron Instituto de Oncología
(VHIO)

Disentangling the 'early-onset cancer epidemic' using environmental and lifestyle-related epigenetic aberrations